Tissue sections were immunohistochemically stained for pERK1/2, pAKT and pp70S6K1 as markers of pathway activation, and tumor-derived DNA was analyzed for mutational status of KRAS exon 2 and BRAF exon 15 by amplicon sequencing. Here, BRAF is linked to neoplasm.